Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
Contracting schemes in medtech: Challenges and opportunities
Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented...